Endocrine Abstracts

Introduction: Targeted therapy with the multi-kinase inhibitor sorafenib is effective for treatment of differentiated thyroid cancer (DTC) unresponsive to RAI. Although kinase-inhibitors (KIs) are usually well tolerated, severe and even fatal adverse events are reported. Aim of the study was to assess incidence and characteristics of fatal events in patients with RAI-refractory DTC responsive to treatment with sorafenib.Design: A retrospective analysis o...

Introduction: Kinase-inhibitors (KIs) are effective for treatment of most aggressive endocrine cancers. The crucial point about treatment with KIs is that these agents are not curative and their effects are at best transitory and are always followed by a restoration of tumour growth and progression. Several retrospective and phase II studies demonstrated efficacy of both sorafenib and sunitib for treatment of iodine refractory differentiated thyroid cancer although results fro...

Context: Primary hyperparathyroidism (PHPT) is a common endocrine disease, characterized by the chronic elevation of serum calcium (Ca) levels induced by a long-standing increase of PTH concentrations. PHPT includes mild-asymptomatic and symptomatic forms. Cinacalcet is effective in lowering serum Ca levels in PHPT, but is indicated solely in mild-asymptomatic PHPT meeting surgery criteria. Management of non-surgical mild-asymptomatic PHPT is still a debated issue.<p class...